Navigation Links
Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
Date:9/26/2013

SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced the full three year long-term follow up results from Phase 2a of the CUPID 1 trial in the online publication of Circulation Research. Phase 2a of the CUPID 1 trial investigated Celladon's product candidate MYDICAR in three dose groups for the treatment of advanced heart failure.

"The long term trends observed in the full three years of follow up from the CUPID 1 trial in the MYDICAR high dose group are very encouraging," said Krisztina Zsebo, Ph.D., President and Chief Executive Officer of Celladon Corporation. "The duration of clinical response in the high dose group, coupled with the favorable trend in mortality and lack of safety concerns, leaves us optimistic for future development of MYDICAR."

In the additional two year follow up period of the CUPID 1 trial, the durability of reduced cardiovascular and terminal events previously observed in the MYDICAR high dose cohort at 12 months was maintained. The following recurrent cardiovascular and terminal events were tracked over the three years in all MYDICAR dose groups: myocardial infarction, worsening heart failure, heart failure-related hospitalization, left ventricular assist device (LVAD) placement, heart transplantation, and all-cause death. The risk of pre-specified recurrent cardiovascular events through full three years of follow up was reduced by 82% in the high dose group compared to the placebo group (p=0.048, where p-value is the statistical probability of a result due to chance alone).

In addition, the survival probability over time was higher for patients in all MYDICAR dose groups compared to the placebo group, especially in the high dose group. At three years post-administration, there we
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
5. Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
6. Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
7. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
8. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
9. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
10. Neogen Corporation Announces 2nd Quarter Results Conference Call
11. Luminex Corporation to Present at JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , ... July 03, 2015 , ... Cuvettes have been used in countless labs for ... to find the cuvette they needed. As expected, this was a daunting and tiring ... wrong part because they were not able to navigate the complex catalog structure. , Now ...
(Date:7/2/2015)... ... ... Sleepless nights will become obsolete as Luzi , a sophisticated smart ... June 23. Sound sleepers and the sleep deprived both will love Luzi for its ... integration of the Bluetooth speaker, alarm clock and ability to charge various devices, including ...
(Date:7/1/2015)... 2015   Decision Resources Group finds ... Otezla are its oral administration, alternative mechanism of ... surveyed rheumatologists. Otezla was the first oral therapy ... active psoriatic arthritis in the United ... includes conventional oral treatments including disease-modifying antirheumatic drugs ...
(Date:7/1/2015)... 2015  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced that the company will ... 5:45 p.m. EDT following its presentation of RVT-101 ... 2015 (AAIC). The event will ... Lawrence Friedhoff , Chief Development Officer, will ...
Breaking Biology Technology:New Cuvette E-Commerce Website Launched by FireflySci 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3
... Live Webcast and Conference Call Scheduled for Monday, March 31st at 5 PM ... ... 26 ImaRx Therapeutics,Inc. (Nasdaq: IMRX ) today announced that the Company ... Monday, March 31,2008, at 5:00 p.m. ET to discuss corporate updates and financial ...
... Source Bioactive Small Molecules through ... ... (Nasdaq:,SIAL) today announced the addition of 1,300 bioactive small molecules ... tool provides expanded data on the functional relationship between,bioactive small ...
... on Thursday, March 27, 2008, (7:00 p.m. Singapore ... MOUNTAIN VIEW, Calif., March 26 ,Alexza Pharmaceuticals, Inc. (Nasdaq: ... one of the largest dedicated biomedical investment,management companies in ... in Alexza. The investment by Bio*One is being made ...
Cached Biology Technology:Sigma-Aldrich Partners With Sunset Molecular Discovery to Expand Your Favorite Gene Search Tool 2Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore 2Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore 3Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore 4Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore 5
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
(Date:6/24/2015)... YORK , June 24, 2015 This ... market, over the next six years. It contains an ... the industry, along with their impact from the short, ... It also discusses the industry, market, and technology trends ... that the need of concerned authorities to efficiently manage ...
(Date:6/23/2015)... , June 22, 2015 ... announced the addition of the "Body-Worn Temperature ... Growth, Trends and Forecast 2014 - 2020" ... offers strategic analysis of the global body-worn temperature ... has been segmented on the basis of types, ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... fibrosis (CF), a chronic disease that clogs the lungs ... a genetic defect in a chloride channel called cystic ... fully understand how or why this defect occurs, a ... (SickKids) in Toronto, Ontario, Canada has found a promising ...
... Oncology (ESMO) has honored three of Europe,s leading medical ... care and research. "The eminent oncologists we ... contributions to the care of patients with cancer," said ... thank them for their unstinting efforts on behalf of ...
... SALT LAKE CITY, Sept. 19, 2011 University ... through walls now are aiming the technology at a ... adults with sleep apnea and babies at risk of ... uses off-the-shelf wireless transceivers similar to those used in ...
Cached Biology News:Unraveling a new regulator of cystic fibrosis 2Oncologists recognized by ESMO for outstanding contributions to cancer research and treatment 2Catching a breath -- wirelessly 2Catching a breath -- wirelessly 3Catching a breath -- wirelessly 4Catching a breath -- wirelessly 5
... 21 CFR part 11, Compliant software for JASCO HPLC systems. ... ... number of control software options for JASCO HPLC systems. This provides ... and record all instrument settings with each run. , ...
... Gel loading solution, Type ... non-denaturing polyacrylamide and agarose ... acids and offers the ... dyes (bromphenol blue and ...
Rabbit polyclonal to QKI...
... Stain for Mass Spectrometry Applications ,In ... (MS) has emerged as a powerful protein ... 2-D gels is now an important intermediate ... leads ultimately to identification of specific proteins ...
Biology Products: